OPTIMAL MANAGEMENT OF ATEZOLIZUMAB PLUS BEVACIZUMAB THERAPY FOR PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA FOCUSING ON THERAPEUTIC MODIFICATIONS

被引：0
|
作者：
Tokunaga, Takayuki [1 ]
Tateyama, Masakuni [1 ]
Kondo, Yasuteru [2 ,3 ]
Miuma, Satoshi [4 ]
Miyase, Shiho [5 ]
Tanaka, Kentaro [1 ]
Narahara, Satoshi [1 ]
Inada, Hiroki [1 ]
Kurano, Sotaro [1 ]
Yoshimaru, Yoko [1 ]
Nagaoka, Katsuya [1 ]
Watanabe, Takehisa [1 ]
Setoyama, Hiroko [1 ]
Tanaka, Yasuhito [1 ]
机构：
[1] Kumamoto Univ, Dept Gastroenterol & Hepatol, Fac Life Sci, Kumamoto, Japan
[2] Sendai Kousei Hosp, Hepatol, Sendai, Japan
[3] Sendai Kousei Hosp, Sendai, Japan
[4] Nagasaki Univ, Grad Sch Biomed Sci, Dept Gastroenterol & Hepatol, Nagasaki, Japan
[5] Kumamoto Shinto Gen Hosp, Dept Gastroenterol & Hepatol, Kumamoto, Japan
来源：
HEPATOLOGY | 2022年 / 76卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
4461
引用
收藏
页码：S1351 / S1352
页数：2
相关论文
共 50 条
  • [21] Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice
    Hayakawa, Yuka
    Tsuchiya, Kaoru
    Kurosaki, Masayuki
    Yasui, Yutaka
    Kaneko, Shun
    Tanaka, Yuki
    Ishido, Shun
    Inada, Kento
    Kirino, Sakura
    Yamashita, Koji
    Nobusawa, Tsubasa
    Matsumoto, Hiroaki
    Kakegawa, Tatsuya
    Higuchi, Mayu
    Takaura, Kenta
    Tanaka, Shohei
    Maeyashiki, Chiaki
    Tamaki, Nobuharu
    Nakanishi, Hiroyuki
    Itakura, Jun
    Takahashi, Yuka
    Asahina, Yasuhiro
    Okamoto, Ryuichi
    Izumi, Namiki
    [J]. INVESTIGATIONAL NEW DRUGS, 2022, 40 (02) : 392 - 402
  • [22] Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice
    Yuka Hayakawa
    Kaoru Tsuchiya
    Masayuki Kurosaki
    Yutaka Yasui
    Shun Kaneko
    Yuki Tanaka
    Shun Ishido
    Kento Inada
    Sakura Kirino
    Koji Yamashita
    Tsubasa Nobusawa
    Hiroaki Matsumoto
    Tatsuya Kakegawa
    Mayu Higuchi
    Kenta Takaura
    Shohei Tanaka
    Chiaki Maeyashiki
    Nobuharu Tamaki
    Hiroyuki Nakanishi
    Jun Itakura
    Yuka Takahashi
    Yasuhiro Asahina
    Ryuichi Okamoto
    Namiki Izumi
    [J]. Investigational New Drugs, 2022, 40 : 392 - 402
  • [23] Safety and efficacy of atezolizumab plus bevacizumab combination therapy in patients with unresectable hepatocellular carcinoma undergoing dialysis: a case series
    Sakaguchi, Koki
    Satoh, Tatsunori
    Kawaguchi, Shinya
    Aoyama, Takuya
    Asahara, Kazuhisa
    Endo, Shinya
    Shirane, Naofumi
    Kanemoto, Hideyuki
    Oba, Noriyuki
    Ohno, Kazuya
    [J]. CLINICAL JOURNAL OF GASTROENTEROLOGY, 2024, 17 (03) : 515 - 522
  • [24] Atezolizumab plus bevacizumab for patients with unresectable hepatocellular carcinoma and high hepatitis B viral load: focusing on hepatic safety and viral kinetics
    Chen, San-Chi
    Tsou, Hsiao-Hui Sophie
    Lee, Teng-Yu
    Wang, Hung-Wei
    Chen, Yen-Hao
    Wang, Tseng-En
    Su, Yung-Yeh
    Yang, Shengshun
    Chiu, Chang-Fang
    Liu, Tsang-Wu
    Cheng, Ann-Lii
    Chen, Li-Tzong
    Hsu, Chiun
    [J]. JOURNAL OF HEPATOLOGY, 2023, 78 : S588 - S589
  • [25] Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational study
    Kai, Machiko
    Hikita, Hayato
    Kazuki, Maesaka
    Tahata, Yuki
    Shinkai, Kazuma
    Doi, Akira
    Ohkawa, Kazuyoshi
    Miyazaki, Masanori
    Ishida, Hisashi
    Matsumoto, Kengo
    Nozaki, Yasutoshi
    Yakushijin, Takayuki
    Sakamori, Ryotaro
    Kaneko, Akira
    Iio, Sadaharu
    Nawa, Takatoshi
    Kakita, Naruyasu
    Morishita, Naoki
    Hiramatsu, Naoki
    Usui, Takeo
    Imanaka, Kazuho
    Doi, Yoshinori
    Sakakibara, Mitsuru
    Yoshida, Yuichi
    Oze, Tsugiko
    Kodama, Takahiro
    Tatsumi, Tomohide
    Takehara, Tetsuo
    [J]. PLOS ONE, 2024, 19 (01):
  • [26] CLINICAL FACTORS ASSOCIATED WITH THE THERAPEUTIC EFFICACY OF ATEZOLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA: A MULTICENTER PROSPECTIVE OBSERVATIONAL STUDY
    Maesaka, Kazuki
    Hikita, Hayato
    Kai, Machiko
    Tahata, Yuki
    Shinkai, Kazuma
    Doi, Akira
    Ohkawa, Kazuyoshi
    Miyazaki, Masanori
    Ishida, Hisashi
    Matsumoto, Kengo
    Nozaki, Yasutoshi
    Yakushijin, Takayuki
    Sakamori, Ryotaro
    Kodama, Takahiro
    Tatsumi, Tomohide
    Takehara, Tetsuo
    [J]. HEPATOLOGY, 2023, 78 : S1813 - S1813
  • [27] Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve
    Tomonari, Tetsu
    Tani, Joji
    Sato, Yasushi
    Tanaka, Hironori
    Tanaka, Takahiro
    Taniguchi, Tatsuya
    Morishita, Akihiro
    Okamoto, Koichi
    Sogabe, Masahiro
    Miyamoto, Hiroshi
    Muguruma, Naoki
    Masaki, Tsutomu
    Takayama, Tetsuji
    [J]. CANCER MEDICINE, 2023, 12 (03): : 2646 - 2657
  • [28] Efficacy of Atezolizumab Plus Bevacizumab Versus Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma: a Meta-analysis
    Mah I Kan Changez
    Maimoona Khan
    Muhammad Uzair
    Muhammad Fawad Tahir
    Maryam Mohsin
    Amna Faiyaz Hussain
    Vania Saqib
    Muhammad Khizer Molani
    Aisha Habib Ahmed
    Saad Khalid
    [J]. Journal of Gastrointestinal Cancer, 2024, 55 : 467 - 481
  • [29] Response prediction model of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: multicenter retrospective study
    Ueno, Masaki
    Kosaka, Hisashi
    Iida, Hiroya
    Ida, Yoshiyuki
    Aoi, Kazunori
    Mori, Haruki
    Miyamoto, Atsushi
    Nishida, Yuko
    Hayami, Shinya
    Kawai, Manabu
    Kaibori, Masaki
    [J]. ONCOLOGY, 2023, 101 (09) : 565 - 574
  • [30] Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma
    Zhang, Xin
    Wang, Jingjing
    Shi, Juanjuan
    Jia, Xiaoli
    Dang, Shuangsuo
    Wang, Wenjun
    [J]. JAMA NETWORK OPEN, 2021, 4 (04)
12345